Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 19/20 | 0.74 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.51 |
| ▸ | RELA | Q04206 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27904564 | 0.91 | S1PR1 (0.69) | S1PR1S1PR3 | |
| SCHEMBL14926463 | 0.90 | S1PR1 (0.76) | S1PR1S1PR3 | |
| SCHEMBL320163 | 0.90 | S1PR1 (0.67) | S1PR1S1PR3NPC1RAB9A | |
| SCHEMBL319532 | 0.88 | S1PR1 (0.65) | S1PR1S1PR3 | |
| Hydrochloric Acid SCHEMBL27904558 | 0.87 | S1PR1 (0.64) | S1PR1S1PR3 | |
| SCHEMBL3756364 | 0.86 | S1PR1 (0.84) | S1PR1NPC1RAB9A | |
| SCHEMBL12997814 | 0.86 | S1PR1 (0.74) | S1PR1S1PR3NPC1NFKB1RAB9A | |
| SCHEMBL14926437 | 0.86 | S1PR1 (0.70) | S1PR1NPC1NFKB1RAB9ANFKB2 | |
| SCHEMBL2771786 | 0.85 | S1PR1 (0.62) | S1PR1S1PR3 | |
| SCHEMBL3761602 | 0.85 | S1PR1 (1.00) | S1PR1S1PR3NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9029405-B2 | 5-(biphenyl-4-yl)-3-phenyl-1,2,4-oxadiazolyl derivatives as ligands on the sphingosine 1-phosphate(SIP)receptors | MERCK SERONO S.A. (CH) | 2015-05-12 | — | — | US | disclosed |
| US-20130116289-A1 | 5-(BIPHENYL-4-YL)-3-PHENYL-1,2,4-OXADIAZOLYL DERIVATIVES AS LIGANDS ON THE SPHINGOSINE 1-PHOSPHATE(SIP)RECEPTORS | MERCK SERONO S.A. (CH) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116289-A1 | 5-(BIPHENYL-4-YL)-3-PHENYL-1,2,4-OXADIAZOLYL DERIVATIVES AS LIGANDS ON THE SPHINGOSINE 1-PHOSPHATE(SIP)RECEPTORS | S1PR1, S1PR5, S1PR2 | S1PR1 1/4885S1PR3 4/4885NPC1 601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.